Journal of Clinical Endocrinology & Metabolism, Vol 75, 558-563, Copyright © 1992 by Endocrine Society

ARTICLES

Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial

ES Surrey and HL Judd
Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, University of California, Los Angeles School of Medicine 90048.

The hypoestrogenic state induced by gonadotropin-releasing hormone agonists (GnRHa) has been shown to suppress symptomatic endometriosis effectively but to elicit vasomotor symptoms and loss of bone mineral density. The role of norethindrone as a supplement to GnRHa in eliminating such side effects was assessed by enrolling 20 patients with symptomatic endometriosis diagnosed laparoscopically in a randomized, prospective, double-blinded trial. All patients received the long-acting GnRHa leuprolide acetate 3.75 mg im every 4 weeks for 24 weeks. Ten patients self-administered norethindrone 5 then 10 mg by mouth daily, whereas the remainder self-administered placebo tablets. Results of this study showed that combination therapy was as effective as GnRHa alone in significantly reducing circulating gonadotropin and estrogen levels (P less than 0.01), extent of visible endometriotic implants (P less than 0.01), and painful symptoms (P less than 0.01). Marked vasomotor and vaginal symptoms experienced by patients given GnRHa alone were minimized in those receiving GnRHa with norethindrone. Lumbar spine bone mineral density loss, measured by dual energy x-ray absorptiometry, was significantly reduced and more completely reversed in patients receiving combination therapy (P less than 0.05). A reversible decrease in high density lipoprotein-cholesterol and increase in low density lipoprotein:high density lipoprotein ratio was noted only in the patients receiving combination therapy, but not in those receiving GnRHa only. The addition of norethindrone to GnRHa is an effective means of treating symptomatic endometriosis while ameliorating side effects induced by GnRHa alone.

This article has been cited by other articles:

				H. Fernandez, C. Lucas, B. Hedon, J.L. Meyer, J.M. Mayenga, and C. Roux One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial Hum. Reprod., June 1, 2004; 19(6): 1465 - 1471. [Abstract] [Full Text] [PDF]

				V. M. RICE Conventional Medical Therapies for Endometriosis Ann. N.Y. Acad. Sci., March 1, 2002; 955(1): 343 - 352. [Abstract] [Full Text] [PDF]

				D. L. OLIVE and E. A. PRITTS The Treatment of Endometriosis: A Review of the Evidence Ann. N.Y. Acad. Sci., March 1, 2002; 955(1): 360 - 372. [Abstract] [Full Text] [PDF]

				D. L. Olive and E. A. Pritts Treatment of Endometriosis N. Engl. J. Med., July 26, 2001; 345(4): 266 - 275. [Full Text] [PDF]

				K. K. Miller and A. Klibanski Amenorrheic Bone Loss J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1775 - 1783. [Full Text]

				S.F. Yim, T.K. Lau, D.S. Sahota, T.K.H. Chung, A.M.Z. Chang, and C.J. Haines Prospective Randomized Study of the Effect of "Add-Back" Hormone Replacement on Vascular Function During Treatment With Gonadotropin-Releasing Hormone Agonists Circulation, October 20, 1998; 98(16): 1631 - 1635. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein, A. Klibanski, A. L. Arnold, T. L. Toth, M. D. Hornstein, and R. M. Neer Prevention of Estrogen Deficiency-Related Bone Loss With Human Parathyroid Hormone-(1-34): A Randomized Controlled Trial JAMA, September 23, 1998; 280(12): 1067 - 1073. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein, A. Klibanski, E. H. Schaefer, M. D. Hornstein, I. Schiff, and R. M. Neer Parathyroid Hormone for the Prevention of Bone Loss Induced by Estrogen Deficiency N. Engl. J. Med., December 15, 1994; 331(24): 1618 - 1623. [Abstract] [Full Text]